



## Trendlines Announces Entry into Subscription Agreements to Raise an Aggregate of S\$20.27 Million

- Deal priced at S\$0.12 per share, a premium of approximately 12% above prevailing market price
- New shares to be subscribed by current and new investors

**Misgav, Israel and Singapore, 20 January 2022** – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”), that invests in and incubates innovation-based medtech and agrifood technologies to fulfill its mission to improve the human condition, announced on 19 January 2022 that it had entered into conditional subscription agreements (each a “**Subscription Agreement**” and collectively, the “**Subscription Agreements**”) with each of the (“**Subscribers**”): (a) the Company’s controlling shareholder, Librae Holdings Limited (“**LH**”); (b) FEA Innovations LLC (“**FEA Innovations**”); (c) Palm Tree IV, LLC (“**Palm Tree**”) and (d) Avztim LLC (“**Avztim**”); to raise approximately S\$20.27<sup>1</sup> million (“**Consideration**”) (“**Proposed Subscription**”). Trendlines intends to issue 168,918,912 new ordinary shares (“**Ordinary Shares**”) at an issue price of S\$0.12 per share (“**Subscription Price**”) through the Proposed Subscription. Payment by the Subscribers will be made in eight (8) equal tranches based on the aggregate number of Ordinary Shares allocated to each of the Subscriber. The Subscribers will have the option to make early payment should they choose to do so prior to such due date of each of the tranche/(s). The Company will be seeking specific shareholders’ approval for the Proposed Subscription at a special general meeting to be convened in due course.

The breakdown of the Ordinary Shares to be subscribed and respective Consideration to be paid is as follows:

<b>Name of Subscriber</b>	<b>Aggregate number of Ordinary Shares subscribed over eight (8) equal tranches</b>	<b>Aggregate consideration (S\$)</b>	<b>As a percentage of the existing share capital <sup>(1)</sup></b>	<b>As a percentage of the enlarged share capital following Completion</b>
LH	99,099,096	11,891,892	12.53%	10.32%
FEA Innovations	28,153,152	3,378,378	3.56%	2.93%
Palm Tree	28,153,152	3,378,378	3.56%	2.93%
Avztim	13,513,512	1,621,621	1.71%	1.41%
<b>Total:</b>	<b>168,918,912</b>	<b>20,270,269</b>	<b>21.35%</b>	<b>17.59%</b>

<sup>1</sup> US\$15,000,000 based on the exchange rate as of 19 January 2022, of 0.74 US\$/S\$.

The Subscription Price represents a premium of approximately 15% to the weighted average price of S\$0.104 per share in the capital of the Company based on the trades done on the SGX-ST on 19 January 2022, being the full market day on which the Subscription Agreements were signed and a premium of approximately 12% to the prevailing market price of S\$0.107 per share in the capital of the Company prior to the signing of the Subscription Agreements.

The Company intends to use the net proceeds of approximately S\$20.1 million from the Proposed Placement in the following manner:

- a) Approximately S\$14.07 million (equivalent to 70% of net proceeds from the Proposed Placement) for direct and indirect investments into new, prospective, or existing portfolio companies of the Group; and
- b) Approximately S\$6.03 million (equivalent to 30% of net proceeds from the proposed placement) for general working capital purposes.

Commenting on the Proposed Subscription, Chair and CEO Steve Rhodes said, *“We are appreciative of the strong support from current and new investors for the Proposed Subscription. We feel this financing, priced at a 12% premium to the prevailing market price, represents investors’ confidence in Trendlines, our portfolio companies, our capabilities and competitive edge, and our transparency and track record, along with our exposure to key industry verticals, medtech and agrifood, as well as the high level ESG value Trendlines offers to its investors. This exercise bolsters our cash resources, enabling us to execute follow-on investments in promising companies and pursue new opportunities, both in Israel and Singapore. Our funnel of investment opportunities remains extremely robust, which makes this Proposed Subscription very timely.”*

Chair and CEO Todd Dollinger added, *“This Proposed Subscription with current and new investors, priced at a premium to the current price, is a vote of confidence from investors on the Company’s stock and is a material manifestation of investors’ confidence in Trendlines’ growth strategy and its ability to deliver strong returns.”*

**About The Trendlines Group Ltd.**

Trendlines invests in and incubates innovation-based medtech and agrifood technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

*The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).*

**Investor Contact Information**

**Israel:**

Shira Zimmerman, The Trendlines Group

[investors@trendlines.com](mailto:investors@trendlines.com)

Tel: +972.72.260.7000

**Singapore:**

Jass Lim, Financial PR

[jass@financialpr.com.sg](mailto:jass@financialpr.com.sg)

Shivam Saraf, Financial PR

[shivam@financialpr.com.sg](mailto:shivam@financialpr.com.sg)

Tel: +65.6438.2990